00000nam 2200000zi 4500 9.885893 CaOODSP 20221107171257 m o d f cr cn||||||||| 200417t20202020onca ob f000 0 eng d 9780660345697 CaOODSP eng rda CaOODSP n-cn--- H82-49/2020E-PDF Budget impact analysis guidelines : guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada. Second edition. Ottawa, ON : Patented Medicine Prices Review Board = Conseil d'examen du prix des médicaments brevetés, 2020. ©2020 1 online resource (iv, 41 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Issued also in French under title: Lignes directrices pour l'analyse de l'incidence du prix d'un médicament : lignes directrices pour l'analyse de l'incidence du prix d'un médicament sur les budgets des régimes d'assurance-médicaments. "June 2020." Issued also in HTML format. Includes bibliographical references (pages 33-34). "Budget impact analyses (BIAs) are used to predict and understand the potential financial impact of introducing a new pharmaceutical into a drug reimbursement system that has finite financial resources. While BIAs focus on the financial impact of the new drug, the value to the overall healthcare system is examined through other economic analyses, such as cost-effectiveness analyses (CEAs). In Canada, BIAs are used to make informed reimbursement decisions. These Guidelines provide a standardized approach and detailed recommendations for developing a BIA for submission to the Canadian Agency for Drugs and Technologies in Health (CADTH) or to one of the participating federal/provincial/territorial (FPT) drug plans"--Introduction, page 1. Drugs Prices Canada. Drugs Economic aspects Canada. Pharmaceutical services insurance Canada. Canada. Patented Medicine Prices Review Board, issuing body. Lignes directrices pour l'analyse de l'incidence du prix d'un médicament : (CaOODSP)9.885895 Budget impact analysis guidelines : (CaOODSP)9.689808 PDF 870 KB https://publications.gc.ca/collections/collection_2020/cepmb-pmprb/H82-49-2020-eng.pdf HTML N/A https://www.canada.ca/en/patented-medicine-prices-review/services/reports-studies/budget-impact-analysis-guidelines.html